Oncoclinicas do Brasil Servicos Medicos S.A.
1.00
BRL
-0.05
(-4.76%)
Oncoclinicas do Brasil Servicos Medicos S.A.
B3:ONCO3
(B3)
Recent
price
1.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
BRL
•
in mil. unless spec.Working Capital
BRL
•
in mil. unless spec.Growth Rates
BRL
•
in mil. unless spec.Quarterly Revenue
BRL
•
in mil. unless spec.Quarterly Earnings Per Share
BRL
•
in mil. unless spec.Quarterly Dividends Per Share
BRL
•
in mil. unless spec.- Similar Companies
- Business
- Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3.SA) operates as one of Brazil's leading oncology groups, providing comprehensive cancer diagnosis, treatment, and care services through a network of specialized hospitals and clinics. The company offers a wide range of core products and services, including medical oncology (chemotherapy and targeted therapies); radiation oncology (external beam radiotherapy, brachytherapy, and stereotactic radiosurgery); surgical oncology across specialties such as breast, colorectal, lung, and head and neck cancers; hematology services for blood disorders; nuclear medicine imaging and therapies (PET-CT scans, SPECT, and radioiodine treatment); palliative care; clinical research trials through partnerships with global pharmaceutical companies; and supportive services like psycho-oncology, nutrition, and pain management. These services are delivered via advanced technologies including linear accelerators, CyberKnife systems, and integrated electronic health records, targeting patients across all cancer stages in both private and public healthcare segments. Founded in 2010 and headquartered in São Paulo, Brazil, Oncoclínicas&Co. primarily serves the Brazilian market with over 130 units across more than 40 cities in 11 states, including key locations in São Paulo, Rio de Janeiro, Minas Gerais, and Paraná; it also maintains international collaborations for patient referrals and research. The company operates in the healthcare industry, focusing on the oncology segment with a vertically integrated model that encompasses outpatient clinics, day hospitals, inpatient facilities, and diagnostic imaging centers. Its business segments include fee-for-service treatments, capitation contracts with health insurers, and public tenders via SUS (Brazil's public health system), serving a diverse customer base of private patients, health plan subscribers, and low-income populations. In recent developments, Oncoclínicas&Co. completed the acquisition of the oncology assets of BP - A Beneficência Portuguesa de São Paulo in early 2024, significantly expanding its presence in São Paulo with additional clinics and advanced radiotherapy equipment. The company announced a major capital increase through a R$1.2 billion share offering in mid-2024 to fund network expansion and debt reduction, followed by the opening of six new units in 2025, including a flagship cancer center in Recife. Additionally, it formed a strategic alliance with AstraZeneca in late 2024 for innovative cell therapy programs and launched a digital telemedicine platform for remote oncology consultations in underserved regions, marking a shift toward hybrid care models amid growing demand.